Siglec-2/CD22 Protein, Human, Recombinant (His, Solution)

产品编号 TMPY-05566

别名: CD22 molecule, SIGLEC-2, SIGLEC2

CD22 is a member of the immunoglobulin superfamily, SIGLEC family of lectins. It is first expressed in the cytoplasm of pro-B and pre-B cells, and on the surface as B cells mature to become IgD+. CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. In addition to its potential role as a mediator of intercellular interactions, signal transduction through CD22 can activate B cells and modulate antigen receptor signaling in vitro. The phenotype of CD22-deficient mice suggests that CD22 is primarily involved in the generation of mature B cells within the bone marrow, blood, and marginal zones of lymphoid tissues. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. As an inhibitory coreceptor of the B-cell receptor (BCR), CD22 plays a critical role in establishing signalling thresholds for B-cell activation. Like other coreceptors, the ability of CD22 to modulate B-cell signalling is critically dependent upon its proximity to the BCR, and this in turn is governed by the binding of its extracellular domain to alpha2,6-linked sialic acid ligands. However, genetic studies in mice reveal that some CD22 functions are regulated by ligand binding, whereas other functions are ligand-independent and may only require expression of an intact CD22 cytoplasmic domain at the B-cell surface. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

TargetMol的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Siglec-2/CD22 Protein, Human, Recombinant (His, Solution)

规格	价格/CNY	货期
25 μg	￥ 2,450	现货
50 μg	￥ 3,800	5日内发货
100 μg	￥ 5,910	5日内发货
200 μg	￥ 9,580	5日内发货

大包装超大折扣，点击咨询

选择批次

COA DATASHEET

更多批次查询请联系客服

生物活性

技术参数

产品性质

参考文献

生物活性

Tested by Flow cytometric analysis of anti-CD22 CAR expression.

产品描述

种属	Human
表达系统	HEK293
标签	His
蛋白编号	P20273-1
别名	CD22 molecule, SIGLEC-2, SIGLEC2
蛋白构建	Recombinant human CD22 (isoform-beta, P20273-1, extracellular domain, Met 1-Arg 687) are conjugated with PE under optimum conditions, the unreacted PE was removed.

缓冲液	Aqueous solution containing 0. 5% BSA and 0. 03%Proclin 300
存储	This reagent is stable for 6 months from date of receipt when stored at 2℃ - 8℃. Protected from prolonged exposure to light. Do not freeze !
运输方式	Shipping at ambient temperature.
研究背景	CD22 is a member of the immunoglobulin superfamily, SIGLEC family of lectins. It is first expressed in the cytoplasm of pro-B and pre-B cells, and on the surface as B cells mature to become IgD+. CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. In addition to its potential role as a mediator of intercellular interactions, signal transduction through CD22 can activate B cells and modulate antigen receptor signaling in vitro. The phenotype of CD22-deficient mice suggests that CD22 is primarily involved in the generation of mature B cells within the bone marrow, blood, and marginal zones of lymphoid tissues. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. As an inhibitory coreceptor of the B-cell receptor (BCR), CD22 plays a critical role in establishing signalling thresholds for B-cell activation. Like other coreceptors, the ability of CD22 to modulate B-cell signalling is critically dependent upon its proximity to the BCR, and this in turn is governed by the binding of its extracellular domain to alpha2,6-linked sialic acid ligands. However, genetic studies in mice reveal that some CD22 functions are regulated by ligand binding, whereas other functions are ligand-independent and may only require expression of an intact CD22 cytoplasmic domain at the B-cell surface. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy